<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02936154</url>
  </required_header>
  <id_info>
    <org_study_id>B7921006</org_study_id>
    <nct_id>NCT02936154</nct_id>
  </id_info>
  <brief_title>Study for MR Formulation of PF-06650833 in Healthy Adult Japanese Subjects</brief_title>
  <official_title>A Phase 1, Double Blind (Sponsor Open), Placebo-controlled, Multiple-dose Study To Evaluate The Tolerability, Safety And Pharmacokinetics Of A Modified Release Formulation Of Pf-06650833 Under Fed Condition In Healthy Adult Japanese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the tolerability, safety and pharmacokinetics of
      PF-06650833 orally administered as modified release tablets in healthy Japanese subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2016</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants experiencing an AE/SAE</measure>
    <time_frame>Day 18</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax)</measure>
    <time_frame>Day 1 and Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration time curve for dosing interval (AUCtau)</measure>
    <time_frame>Day 1 and Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to peak concentration</measure>
    <time_frame>Day 1 and Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance</measure>
    <time_frame>Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution</measure>
    <time_frame>Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed exposure accumulation ratio for AUCtau</measure>
    <time_frame>Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed exposure accumulation ratio for Cmax</measure>
    <time_frame>Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum plasma concentration (Cmin)</measure>
    <time_frame>Days 2, 4, 7 and 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fluctuation ratio (Cmax:Cmin)</measure>
    <time_frame>Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean residence time</measure>
    <time_frame>Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline in vital signs</measure>
    <time_frame>Day 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change form baseline in electrocardiogram (ECG) parameters</measure>
    <time_frame>Day 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment emergent clinical laboratory abnormalities</measure>
    <time_frame>Day 18</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>300 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06650833</intervention_name>
    <arm_group_label>300 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy female subjects of non childbearing potential and/or male Japanese subjects
             between the ages of 20 and 55 years, inclusive.

          2. Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight &gt;50 kg (110 lbs).

          3. Subject must have four Japanese grandparents who were born in Japan.

          4. Evidence of a personally signed and dated informed consent document.

          5. Subjects who are willing and able to comply with all scheduled visits, treatment plan,
             laboratory tests, and other study procedures.

        Exclusion Criteria:

          1. Evidence or history of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
             allergic disease.

          2. Any condition possibly affecting drug absorption (eg, gastrectomy).

          3. A positive urine drug screen.

          4. Smoking cigarettes with exceeding provided criteria.

          5. History of regular alcohol consumption exceeding provided limitations.

          6. Treatment with an investigational drug within a provided criteria.

          7. Abnormal supine blood pressure.

          8. Abnormal pulse rate.

          9. Abnormal 12 lead ECG.

         10. History of tuberculosis.

         11. History of hepatitis or positive testing for HIV, hepatitis B surface antigen,
             hepatitis B surface antibodies, hepatitis B core antibodies, hepatitis C antibodies or
             syphilis.

         12. Any medical history of disease (ie, Gilbert's disease).

         13. Abnormal clinical laboratory test related to cardiac and skeletal muscle injury.

         14. Male subjects with partners currently pregnant; unwilling or unable to use a highly
             effective method of contraception

         15. Use of prescription or nonprescription drugs, vitaminic and dietary supplements within
             a specified duration.

         16. Blood donation exceeding a provided limitation.

         17. History of sensitivity to heparin or heparin induced thrombocytopenia.

         18. History of cancer (other than treated basal cell and squamous cell carcinoma of the
             skin) in the previous 5 years.

         19. Unwilling or unable to comply with the Lifestyle guidelines described in this
             protocol.

         20. Subjects who are investigational site staff members directly involved in the conduct
             of the study and their family members, site staff members otherwise supervised by the
             Investigator, or subjects who are Pfizer employees directly involved in the conduct of
             the study.

         21. Other severe acute or chronic medical or psychiatric condition or laboratory
             abnormality.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>P-one Clinic, Keikokai Medical Corporation</name>
      <address>
        <city>Hachioji-shi</city>
        <state>Tokyo</state>
        <zip>192-0071</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B7921006&amp;StudyName=A+Phase+1%2C+Double+Blind+%28sponsor+Open%29%2C+Placebo-controlled%2C+Multiple-dose+Study+To+Evaluate+The+Tolerability%2C+Safety+And+Pharmacokinetics+Of+A+Modified+Release+Formulation+Of+Pf-06650833+Under+Fed+Condition+In+Healthy+Adult+Japanese+Subjects</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 8, 2016</study_first_submitted>
  <study_first_submitted_qc>October 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 18, 2016</study_first_posted>
  <last_update_submitted>October 17, 2017</last_update_submitted>
  <last_update_submitted_qc>October 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

